Protagonist Therapeutics, Inc.
PTGX
Ранг среди акций
#2299
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Цена акции
$134.37
Последняя синхронизация: 2026-10-19
Рыночная капитализация
$8.70B
Изменение (1 день)
4.37%
Изменение (1 год)
75.15%
Страна
US
Торговля Protagonist Therapeutics, Inc. (PTGX)
Категория
Healthcare
EPS для Protagonist Therapeutics, Inc. (PTGX)
EPS по состоянию на June 2026 TTM: $1.22
Согласно последним финансовым отчетам и цене акций Protagonist Therapeutics, Inc., текущий EPS компании (TTM) составляет $1.22. В конце 2023 EPS компании составлял $-1.39, меньше, чем показателю 2022 года, равному $-2.52.
История EPS компании Protagonist Therapeutics, Inc. с 2014 по 2026
EPS на конец каждого года
| Год | EPS | Изменить |
|---|---|---|
| 2026 (TTM) | $1.22 | -72.71% |
| 2024 | $4.47 | -421.58% |
| 2023 | $-1.39 | -44.84% |
| 2022 | $-2.52 | -4.91% |
| 2021 | $-2.65 | 38.02% |
| 2020 | $-1.92 | -35.57% |
| 2019 | $-2.98 | 71.26% |
| 2018 | $-1.74 | -16.75% |
| 2017 | $-2.09 | -63.46% |
| 2016 | $-5.72 | 126.98% |
| 2015 | $-2.52 | 34.04% |
| 2014 | $-1.88 | 0.00% |
EPS для аналогичных компаний или конкурентов
| Компания | EPS | Разница в EPS | Страна |
|---|---|---|---|
| $17.32 | 1,319.67% |
US
|
|
| $-7.98 | -754.10% |
US
|
|
| $-5.29 | -533.61% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 2,173.77% |
NL
|
